Search research articles
Contact Us
Filters
Showing results (81-90 of 248) with videos related to
Page
of 25
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
January 1, 1992
Effects of five daily 1 h infusions of alendronate in Paget's disease of bone
D P O'Doherty, B J Gertz, W Tindale, et al.
Circulation
|
November 7, 2001
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
M A Konstam, M R Weir, A Reicin, et al.
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society
|
July 4, 2001
Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment, and mild dementia
M Grunwald, F Busse, A Hensel, et al.
The Clinical Journal of Pain
|
September 5, 2015
The Associations Between Pain-related Beliefs, Pain Intensity, and Patient Functioning: Hypnotizability as a Moderator
Mark P Jensen, Peter D Galer, Linea L Johnson, et al.
British Journal of Clinical Pharmacology
|
May 1, 1997
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability
D E Newby, D G Sciberras, C M Mendel, et al.
JPEN. Journal of Parenteral and Enteral Nutrition
|
July 13, 2018
Early Enteral Nutrition Is Associated With Significantly Lower Hospital Charges in Critically Ill Children
Theresa A Mikhailov, Shira J Gertz, Evelyn M Kuhn, et al.
Journal of Clinical Pharmacology
|
February 8, 2002
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers
Jules I Schwartz, Peggy H Wong, Arturo G Porras, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 10, 2001
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
M G Murphy, S Weiss, M McClung, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 19, 1998
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
M G Murphy, L M Plunkett, B J Gertz, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
July 15, 1999
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group
M G Murphy, M A Bach, D Plotkin, et al.
Page
of 25
Search research articles
Search
Showing results (81-90 of 248) with videos related to
Sort By:
Page
of 25
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
January 1, 1992
Effects of five daily 1 h infusions of alendronate in Paget's disease of bone
D P O'Doherty, B J Gertz, W Tindale, et al.
Circulation
|
November 7, 2001
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
M A Konstam, M R Weir, A Reicin, et al.
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society
|
July 4, 2001
Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment, and mild dementia
M Grunwald, F Busse, A Hensel, et al.
The Clinical Journal of Pain
|
September 5, 2015
The Associations Between Pain-related Beliefs, Pain Intensity, and Patient Functioning: Hypnotizability as a Moderator
Mark P Jensen, Peter D Galer, Linea L Johnson, et al.
British Journal of Clinical Pharmacology
|
May 1, 1997
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability
D E Newby, D G Sciberras, C M Mendel, et al.
JPEN. Journal of Parenteral and Enteral Nutrition
|
July 13, 2018
Early Enteral Nutrition Is Associated With Significantly Lower Hospital Charges in Critically Ill Children
Theresa A Mikhailov, Shira J Gertz, Evelyn M Kuhn, et al.
Journal of Clinical Pharmacology
|
February 8, 2002
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers
Jules I Schwartz, Peggy H Wong, Arturo G Porras, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 10, 2001
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
M G Murphy, S Weiss, M McClung, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 19, 1998
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
M G Murphy, L M Plunkett, B J Gertz, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
July 15, 1999
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group
M G Murphy, M A Bach, D Plotkin, et al.
Page
of 25